Distribution of (7α)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]- 7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3- propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(α)anthracene- induced mammary tumor

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 331-338

  Yamaya, Hidetoshi ^a   Saeki, Mayuko ^a   Yoshida, Ken Ichiro ^a   Shibata, Jiro ^a   Yano, Shingo ^a   Sato, Yoshiaki ^b   Takao, Atsushi ^b   Shindo, Takashi ^a   Buzdar, Aman U ^c   Nagayama, Sekio ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(7 ALPHA) 21 [4 [(DIETHYLAMINO)METHYL] 2 METHOXYPHENOXY] 7 METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL 2 HYDROXY 1,2,3 PROPANETRICARBOXYLATE; (7 ALPHA) 21 [4 [(DIETHYLAMINO)METHYL] 2 METHOXYPHENOXY] 7 METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL N OXIDE; (7 ALPHA) 21 [4 [(ETHYLAMINO)METHYL] 2 METHOXYPHENOXY] 3 METHOXY 7 METHYL 19 NORPREGNA 1,3,5(10) TRIENE; (7 ALPHA) 21 [4 [(ETHYLAMINO)METHYL] 2 METHOXYPHENOXY] 7 METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 3 METHOXY 4 [(7 ALPHA) 7 METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL 21 YL]OXYBENZOIC ACID; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTIESTROGEN; CARBON 14; DRUG METABOLITE; UNCLASSIFIED DRUG; CARBON; DRUG DERIVATIVE; ESTRADIOL; TS 108;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; ISOTOPE LABELING; LIVER; LUNG; NONHUMAN; OVARY; PLASMA; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPLEEN; TOXICITY; UTERUS; ANIMAL; AUTORADIOGRAPHY; BLOOD; CARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALIA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; AUTORADIOGRAPHY; BREAST NEOPLASMS; CARBON RADIOISOTOPES; CARCINOMA; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; LIVER; NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; UTERUS;

EID: 31344482129     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005504     Document Type: Article

References (15)

1. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, et al. (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 61:97-106.
2. Fromson JM, Pearson S, and Bramah S (1973a) The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica 3:693-709.
3. Fromson JM, Pearson S, and Bramah S (1973b) The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 3:711-714.
4. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, and Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863-870.
5. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, and Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175-2183.
6. Lien EA, Solheim E, and Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844.
7. Major JS, Green B, and Heald PJ (1976) Interactions of oestradiol-17beta and tamoxifen in the uterus of the pregnant rat. J Endocrinol 71:315-324.
8. Pujol H, Girault J, Rouanet P, Fournier S, Grenier J, Simony J, Fourtillan JB, and Pujol JL (1995) Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol 36:493-498.
9. Robinson SP, Langan-Fahey SM, Johnson DA, and Jordan VC (1991) Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43.
10. Ruenitz PC and Bagley JR (1985) Comparative fates of clomiphene and tamoxifen in the immature female rat. Drug Metab Dispos 13:582-586.
11. Shibata J, Shindo T, Hashimoto A, Wierzba K, Yamamoto Y, Sakai K, Toko T, Yano S, Matsuo K, and Kitazato K (2002) The anticancer activity of a new antiestrogenic agent, TAS-108 (SR16234), against DMBA-induced mammary tumors in rats is partly mediated by deEt-TAS-108, its potent metabolite exerting strong antagonistic properties. Eur J Cancer 38:S98.
12. Toko T, Shibata J, Sugimoto Y, Yamaya H, Yoshida M, Ogawa K, and Matsushima E (1995) Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol 37:7-13.
13. 14C-labelled tamoxifen in spayed female mice. Acta Pharmacol Toxicol (Copenh) 50:161-168.
14. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, and Terada T (2005) TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect. Clin Cancer Res 11:315-322.
15. Yamamoto Y, Wada O, Takada I, Yogiashi Y, Shibata J, Yanagisawa J, Kitazato K, and Kato S (2003) Both N- and C-terminal transactivation functions of DNA-bound ER are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun 312:656-662.